Drugs / DC-CIK

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07343791 Nov 2025 → Nov 2027 expected colorectal cancer JIANG LONGWEI Recruiting No outcome recorded
Phase 1/28 trials
Phase 1/2 NCT05622825 Jan 2023 → Dec 2024 liver cancer National Taiwan University Hospital Unknown No outcome recorded
Phase 1/2 NCT03393858 Dec 2017 → Dec 2021 malignant mesothelioma Capital Medical University Terminated No outcome recorded
Phase 1/2 NCT02425748 Jun → Dec 2017 lung cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT03047525 Feb 2017 → Jan 2019 colorectal cancer, lung cancer, nasopharyngeal carcinoma, renal cell carcinoma Xiaoyi Huang Unknown No outcome recorded
Phase 1/2 NCT03360630 Nov 2016 → Dec 2022 lung cancer Capital Medical University Completed No outcome recorded
Phase 1/2 NCT02418481 Apr 2015 → Jun 2016 breast cancer Fuda Cancer Hospital, Guangzhou Completed No outcome recorded
Phase 1/2 NCT01781520 Jun 2013 → May 2016 malignant pancreatic neoplasm Capital Medical University Completed No outcome recorded
Phase 1/2 NCT01783951 Feb 2013 → Feb 2018 gastric cancer Capital Medical University Completed No outcome recorded
Phase 24 trials
Phase 2 NCT02491697 Feb 2016 → Aug 2030 expected breast cancer The First People's Hospital of Changzhou Active not recruiting No outcome recorded
Phase 2 NCT02644863 Dec 2015 → Dec 2018 esophageal cancer Shenzhen Hornetcorn Bio-technology Company, LTD Unknown No outcome recorded
Phase 2 NCT02487017 May 2015 → Dec 2018 hepatocellular carcinoma Shenzhen Hornetcorn Bio-technology Company, LTD Unknown No outcome recorded
Phase 2 NCT02202928 Jul 2014 → Dec 2017 colorectal cancer Shenzhen Hornetcorn Bio-technology Company, LTD Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02415699 Aug 2015 → Jul 2017 colorectal cancer Sixth Affiliated Hospital, Sun Yat-sen University Unknown No outcome recorded
Phase not applicable3 trials
NCT04214717 Dec 2019 → Dec 2023 cancer Yantai Yuhuangding Hospital Unknown No outcome recorded
NCT03158480 Jun 2017 → Dec 2018 anogenital human papillomavirus infection Shenzhen Second People's Hospital Unknown No outcome recorded
NCT01906632 May 2013 → Dec 2022 cancer Capital Medical University Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04292769 Background Jan 2020 → Jan 2023 cancer Li Yu Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as DC-CIK “Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment” NCT03047525
16

NCT02644863

NCT04214717

NCT01781520

NCT02418481

NCT03158480

NCT05622825

NCT04292769

NCT02425748

NCT03393858

NCT02487017

NCT02202928

NCT07343791

NCT02491697

NCT01783951

NCT03360630

NCT02415699

Known as D-CIK “Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16,...” NCT02644863
Known as DC-CIK Immunotherapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT01906632
Known as Dendritic and Cytokine-induced Killer Cells “Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells...” NCT03047525
Modality Cell therapy “cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.” NCT01781520
Route Intravenous “IV (in the vein)” NCT02202928